The global Genetic Disease Testing market size is predicted to grow from US$ 1044 million in 2025 to US$ 2056 million in 2031; it is expected to grow at a CAGR of 12.0% from 2025 to 2031.
Genetic disease testing, also known as genetic testing, involves analyzing chromosomes, genes, or proteins to identify changes that may lead to genetic disorders. This testing can confirm or rule out suspected genetic conditions or assess the risk of developing or passing on genetic disorders.
麻豆原创 Development Overview:
In recent years, the genetic disease testing market has seen substantial growth due to advances in genomics, increased awareness of genetic diseases, and growing demand for personalized medicine. The global genetic disease testing market was valued at billions of dollars in 2023 and is expected to expand at a significant compound annual growth rate (CAGR) in the coming years. Factors driving this growth include technological advances in next-generation sequencing (NGS), declining costs of genetic testing, and expanding applications in oncology, rare disease diagnosis, and reproductive health. Governments and healthcare organizations around the world are actively promoting genetic screening programs, further driving market expansion. Direct-to-consumer (DTC) genetic testing is also becoming increasingly popular, with companies offering home testing kits for health risk assessment and ancestry tracing. The market is expected to maintain steady growth as regulators create clearer guidelines for genetic testing services.
麻豆原创 Development Opportunities:
Next-generation sequencing (NGS) and CRISPR gene editing technologies are revolutionizing genetic testing, enabling faster, more accurate, and more cost-effective diagnoses. The reduction in the cost of whole genome sequencing makes genetic testing more accessible to a wider range of people. As healthcare shifts toward personalized treatment plans, genetic testing is becoming an important tool to tailor treatments to patients鈥� genetic profiles. Precision oncology in particular benefits from genetic insights that enable targeted cancer treatments. Many rare genetic diseases remain undiagnosed due to the complexity of traditional diagnostic methods. Advances in genetic testing are improving early detection and management of these diseases, creating new market opportunities. With consumers鈥� growing interest in health and ancestry, demand for direct-to-consumer genetic testing companies has surged. Companies are also developing AI-driven analytics to provide more personalized insights from genetic data.
麻豆原创 Risks and Challenges:
Genetic testing raises ethical questions about data privacy, consent, and potential misuse of genetic information. Governments are implementing stricter regulations, which could impact market growth if compliance costs increase. As genetic testing companies collect large amounts of sensitive personal data, the risk of data breaches and misuse continues to increase. Ensuring secure storage and ethical use of genetic data is a key concern for industry stakeholders. Despite declining sequencing costs, genetic testing remains expensive in many regions, limiting accessibility to low-income populations. Insurance coverage for genetic testing also varies, impacting adoption rates. Without appropriate genetic counseling, consumers and patients may misinterpret test results, leading to unnecessary anxiety or inappropriate medical decisions. Expanding access to genetic counseling services is critical to mitigating this risk.
The 鈥淕enetic Disease Testing Industry Forecast鈥� looks at past sales and reviews total world Genetic Disease Testing sales in 2024, providing a comprehensive analysis by region and market sector of projected Genetic Disease Testing sales for 2025 through 2031. With Genetic Disease Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Genetic Disease Testing industry.
This Insight Report provides a comprehensive analysis of the global Genetic Disease Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Genetic Disease Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Genetic Disease Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Genetic Disease Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Genetic Disease Testing.
This report presents a comprehensive overview, market shares, and growth opportunities of Genetic Disease Testing market by product type, application, key players and key regions and countries.
Segmentation by Type:
Direct Genetic Testing
Indirect Genetic Testing
Segmentation by Application:
Carrier Testing
Prenatal Testing
Newborn Screening
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Invitae
Ambry Genetics
Exact Sciences
Qiagen
Tempus
23andme
Veritas Genetics
Myriad Genetics
LabCorp
Blueprint Genetics
Illumina
CENTOGENE
GeneDx
Fulgent Genetics
BGI Genomics
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Genetic Disease Testing 麻豆原创 Size (2020-2031)
2.1.2 Genetic Disease Testing 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Genetic Disease Testing by Country/Region (2020, 2024 & 2031)
2.2 Genetic Disease Testing Segment by Type
2.2.1 Direct Genetic Testing
2.2.2 Indirect Genetic Testing
2.3 Genetic Disease Testing 麻豆原创 Size by Type
2.3.1 Genetic Disease Testing 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Genetic Disease Testing 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Genetic Disease Testing Segment by Application
2.4.1 Carrier Testing
2.4.2 Prenatal Testing
2.4.3 Newborn Screening
2.4.4 Others
2.5 Genetic Disease Testing 麻豆原创 Size by Application
2.5.1 Genetic Disease Testing 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Genetic Disease Testing 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Genetic Disease Testing 麻豆原创 Size by Player
3.1 Genetic Disease Testing 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Genetic Disease Testing Revenue by Player (2020-2025)
3.1.2 Global Genetic Disease Testing Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Genetic Disease Testing Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Genetic Disease Testing by Region
4.1 Genetic Disease Testing 麻豆原创 Size by Region (2020-2025)
4.2 Global Genetic Disease Testing Annual Revenue by Country/Region (2020-2025)
4.3 Americas Genetic Disease Testing 麻豆原创 Size Growth (2020-2025)
4.4 APAC Genetic Disease Testing 麻豆原创 Size Growth (2020-2025)
4.5 Europe Genetic Disease Testing 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Genetic Disease Testing 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Genetic Disease Testing 麻豆原创 Size by Country (2020-2025)
5.2 Americas Genetic Disease Testing 麻豆原创 Size by Type (2020-2025)
5.3 Americas Genetic Disease Testing 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Genetic Disease Testing 麻豆原创 Size by Region (2020-2025)
6.2 APAC Genetic Disease Testing 麻豆原创 Size by Type (2020-2025)
6.3 APAC Genetic Disease Testing 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Genetic Disease Testing 麻豆原创 Size by Country (2020-2025)
7.2 Europe Genetic Disease Testing 麻豆原创 Size by Type (2020-2025)
7.3 Europe Genetic Disease Testing 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Genetic Disease Testing by Region (2020-2025)
8.2 Middle East & Africa Genetic Disease Testing 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Genetic Disease Testing 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Genetic Disease Testing 麻豆原创 Forecast
10.1 Global Genetic Disease Testing Forecast by Region (2026-2031)
10.1.1 Global Genetic Disease Testing Forecast by Region (2026-2031)
10.1.2 Americas Genetic Disease Testing Forecast
10.1.3 APAC Genetic Disease Testing Forecast
10.1.4 Europe Genetic Disease Testing Forecast
10.1.5 Middle East & Africa Genetic Disease Testing Forecast
10.2 Americas Genetic Disease Testing Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Genetic Disease Testing Forecast
10.2.2 Canada 麻豆原创 Genetic Disease Testing Forecast
10.2.3 Mexico 麻豆原创 Genetic Disease Testing Forecast
10.2.4 Brazil 麻豆原创 Genetic Disease Testing Forecast
10.3 APAC Genetic Disease Testing Forecast by Region (2026-2031)
10.3.1 China Genetic Disease Testing 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Genetic Disease Testing Forecast
10.3.3 Korea 麻豆原创 Genetic Disease Testing Forecast
10.3.4 Southeast Asia 麻豆原创 Genetic Disease Testing Forecast
10.3.5 India 麻豆原创 Genetic Disease Testing Forecast
10.3.6 Australia 麻豆原创 Genetic Disease Testing Forecast
10.4 Europe Genetic Disease Testing Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Genetic Disease Testing Forecast
10.4.2 France 麻豆原创 Genetic Disease Testing Forecast
10.4.3 UK 麻豆原创 Genetic Disease Testing Forecast
10.4.4 Italy 麻豆原创 Genetic Disease Testing Forecast
10.4.5 Russia 麻豆原创 Genetic Disease Testing Forecast
10.5 Middle East & Africa Genetic Disease Testing Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Genetic Disease Testing Forecast
10.5.2 South Africa 麻豆原创 Genetic Disease Testing Forecast
10.5.3 Israel 麻豆原创 Genetic Disease Testing Forecast
10.5.4 Turkey 麻豆原创 Genetic Disease Testing Forecast
10.6 Global Genetic Disease Testing Forecast by Type (2026-2031)
10.7 Global Genetic Disease Testing Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Genetic Disease Testing Forecast
11 Key Players Analysis
11.1 Invitae
11.1.1 Invitae Company Information
11.1.2 Invitae Genetic Disease Testing Product Offered
11.1.3 Invitae Genetic Disease Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Invitae Main Business Overview
11.1.5 Invitae Latest Developments
11.2 Ambry Genetics
11.2.1 Ambry Genetics Company Information
11.2.2 Ambry Genetics Genetic Disease Testing Product Offered
11.2.3 Ambry Genetics Genetic Disease Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Ambry Genetics Main Business Overview
11.2.5 Ambry Genetics Latest Developments
11.3 Exact Sciences
11.3.1 Exact Sciences Company Information
11.3.2 Exact Sciences Genetic Disease Testing Product Offered
11.3.3 Exact Sciences Genetic Disease Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Exact Sciences Main Business Overview
11.3.5 Exact Sciences Latest Developments
11.4 Qiagen
11.4.1 Qiagen Company Information
11.4.2 Qiagen Genetic Disease Testing Product Offered
11.4.3 Qiagen Genetic Disease Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Qiagen Main Business Overview
11.4.5 Qiagen Latest Developments
11.5 Tempus
11.5.1 Tempus Company Information
11.5.2 Tempus Genetic Disease Testing Product Offered
11.5.3 Tempus Genetic Disease Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Tempus Main Business Overview
11.5.5 Tempus Latest Developments
11.6 23andme
11.6.1 23andme Company Information
11.6.2 23andme Genetic Disease Testing Product Offered
11.6.3 23andme Genetic Disease Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 23andme Main Business Overview
11.6.5 23andme Latest Developments
11.7 Veritas Genetics
11.7.1 Veritas Genetics Company Information
11.7.2 Veritas Genetics Genetic Disease Testing Product Offered
11.7.3 Veritas Genetics Genetic Disease Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Veritas Genetics Main Business Overview
11.7.5 Veritas Genetics Latest Developments
11.8 Myriad Genetics
11.8.1 Myriad Genetics Company Information
11.8.2 Myriad Genetics Genetic Disease Testing Product Offered
11.8.3 Myriad Genetics Genetic Disease Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Myriad Genetics Main Business Overview
11.8.5 Myriad Genetics Latest Developments
11.9 LabCorp
11.9.1 LabCorp Company Information
11.9.2 LabCorp Genetic Disease Testing Product Offered
11.9.3 LabCorp Genetic Disease Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 LabCorp Main Business Overview
11.9.5 LabCorp Latest Developments
11.10 Blueprint Genetics
11.10.1 Blueprint Genetics Company Information
11.10.2 Blueprint Genetics Genetic Disease Testing Product Offered
11.10.3 Blueprint Genetics Genetic Disease Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Blueprint Genetics Main Business Overview
11.10.5 Blueprint Genetics Latest Developments
11.11 Illumina
11.11.1 Illumina Company Information
11.11.2 Illumina Genetic Disease Testing Product Offered
11.11.3 Illumina Genetic Disease Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Illumina Main Business Overview
11.11.5 Illumina Latest Developments
11.12 CENTOGENE
11.12.1 CENTOGENE Company Information
11.12.2 CENTOGENE Genetic Disease Testing Product Offered
11.12.3 CENTOGENE Genetic Disease Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 CENTOGENE Main Business Overview
11.12.5 CENTOGENE Latest Developments
11.13 GeneDx
11.13.1 GeneDx Company Information
11.13.2 GeneDx Genetic Disease Testing Product Offered
11.13.3 GeneDx Genetic Disease Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 GeneDx Main Business Overview
11.13.5 GeneDx Latest Developments
11.14 Fulgent Genetics
11.14.1 Fulgent Genetics Company Information
11.14.2 Fulgent Genetics Genetic Disease Testing Product Offered
11.14.3 Fulgent Genetics Genetic Disease Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Fulgent Genetics Main Business Overview
11.14.5 Fulgent Genetics Latest Developments
11.15 BGI Genomics
11.15.1 BGI Genomics Company Information
11.15.2 BGI Genomics Genetic Disease Testing Product Offered
11.15.3 BGI Genomics Genetic Disease Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 BGI Genomics Main Business Overview
11.15.5 BGI Genomics Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.